RGC
TEVA icon

Roberts, Glore & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Roberts, Glore & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,570
Closed -$211K – 142
2017
Q1 		$211K Sell
6,570
-8,230
-56% -$281K 0.15% 135
2016
Q4 		$537K Sell
14,800
-2,925
-17% -$117K 0.37% 77
2016
Q3 		$816K Sell
17,725
-225
-1% -$11.7K 0.59% 53
2016
Q2 		$902K Buy
17,950
+20
+0.1% +$1.06K 0.68% 47
2016
Q1 		$959K Sell
17,930
-575
-3% -$33.7K 0.73% 43
2015
Q4 		$1.22M Sell
18,505
-300
-2% -$18.5K 0.92% 35
2015
Q3 		$1.06M Sell
18,805
-7,645
-29% -$496K 0.83% 38
2015
Q2 		$1.56M Sell
26,450
-625
-2% -$38.6K 1.09% 28
2015
Q1 		$1.69M Sell
27,075
-205
-0.8% -$11.9K 1.16% 26
2014
Q4 		$1.57M Buy
27,280
+215
+0.8% +$12K 1.05% 31
2014
Q3 		$1.46M Sell
27,065
-935
-3% -$49.5K 1.01% 31
2014
Q2 		$1.47M Sell
28,000
-750
-3% -$38.3K 1% 34
2014
Q1 		$1.52M Sell
28,750
-1,600
-5% -$73.9K 1.05% 30
2013
Q4 		$1.22M Buy
30,350
+1,775
+6% +$69.9K 0.84% 39
2013
Q3 		$1.08M Sell
28,575
-10,000
-26% -$390K 0.8% 40
2013
Q2 		$1.51M Buy
+38,575
New +$1.5M 0.93% 36

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Roberts, Glore & Co's TEVA Position: Q2 2017 in Review

Roberts, Glore & Co sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 6,570 shares — an estimated $211K sold.

Roberts, Glore & Co first reported a position in TEVA in Q2 2013 and held it in 16 quarters. The position peaked at $1.69M in Q1 2015. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Roberts, Glore & Co reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Roberts, Glore & Co sold 6,570 Teva Pharmaceuticals shares in Q2 2017, an estimated $211K.
  • Roberts, Glore & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 16 quarters.
  • Roberts, Glore & Co's Teva Pharmaceuticals position peaked at $1.69M in Q1 2015.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Roberts, Glore & Co's 13F filing for Q2 2017, filed 15 Aug 2017.